10x Genomics, Inc. (TXG) Stock: Price, Forecast & Analyst Target
10x Genomics, Inc. (TXG) — MoonshotScore 38/100 (Weak band), calculated Nov 18, 2026. Price $57.07 (+1.37%), as of the Nov 18, 2026 trading session; market cap $7.51B. Expected results Feb 11, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 13.05× (cash as of Sep 30, 2026) · expected results Feb 11, 2027
10x Genomics, Inc. · TXG · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: TXG sells instruments, experiment-specific consumables and software that let researchers examine biology at cell-resolved and spatial levels; it is a life-science tools supplier, not a drug developer. The case depends on whether Atera can revive spatial demand while recurring Chromium consumables sustain growth and the cost base moves toward durable profitability.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · 10x Genomics (TXG)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and a strong balance sheet, but an expensive valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Sound; Valuation: Rich; Growth Durability: Growing; Momentum: Surging.
Enterprise value relative to EBITDA is the main valuation drag relative to sector peers.
- EPS beat 6 of the last 8 reports
- Altman Z 17.41 · Piotroski F 5
- ROE -8.2% · ROA -6.3% · current ratio 5.12 · earnings yield -0.9% · free-cash-flow yield 1.4%
Holding back: a rich price
Helping: business quality, balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 39 | Weak | |
| 39 | Weak | |
| 39 | Weak | |
| 39 | Weak | |
| 38 | Weak | |
| 38 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $57.07 | |
| Change on the day | +1.37% | |
| 52-week range | $15.18–$102.81 | |
| Market capitalisation | $7.51B | — |
| Shares traded on the day | 2.10M | |
| Beta (volatility vs the S&P 500) | 2.03 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Additionally, as Atera instrument shipments ramp in the fourth quarter, we expect gross margins to step down sequentially.
Adam Taich · Statement from
So like as we said, we expect to ship about 50 units by the end of this year.
Serge Saxonov · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for 10x Genomics (TXG): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is 10x Genomics (TXG), and what does it report?
Short answer · as of
Chromium and Chromium Connect prepare and analyze biological samples, while Visium maps gene activity within tissue.
Research dated 2026-09-13.
Academic, government, biotechnology and biopharmaceutical laboratories buy the instruments and then use proprietary chips, slides and reagents as experiments run.
Reported revenue therefore measures much more than equipment placements. Consumables provide the dominant stream, with smaller contributions from instruments, services, licensing and royalties; experiment activity on the installed platforms matters more than instrument shipments alone.
What do the latest results show for 10x Genomics (TXG)?
Research dated 2026-09-13.
Revenue was nearly flat sequentially in the latest period but remained below the comparable prior period. Gross profit improved from the immediately preceding period, yet higher selling and administrative expense accompanied a wider operating and net loss; operating cash flow stayed positive.
Recent reports have generally exceeded revenue expectations, but that has not restored consistent accounting profitability. Management attributes the expected near-term revenue step-down to the spatial platform transition and expects Atera shipments to become a more meaningful contributor later.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $150.67M Sep 30, 2026
- Latest quarter · R&D
- $52.93M Sep 30, 2026
- Latest quarter · SG&A
- $76.06M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- −$16.06M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $150.67M | $52.93M | $76.06M | −$16.06M |
| Jun 30, 2026 | $151.04M | $56.79M | $78.66M | −$19.55M |
| Mar 31, 2026 | $150.84M | $56.85M | $66.38M | −$17.05M |
| Dec 31, 2025 | $166.03M | $55.97M | $76.62M | −$19.54M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $150.67M Nov 5, 2026
- Latest report · revenue estimate
- $147.96M Nov 5, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 5, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 5, 2026 | $150.67M | $147.96M | −$0.1500 | −$0.2670 |
| Aug 6, 2026 | $151.04M | $146.67M | −$0.1400 | −$0.2431 |
| May 7, 2026 | $150.84M | $146.41M | −$0.1000 | −$0.2900 |
| Feb 12, 2026 | $166.03M | $159.65M | −$0.1300 | −$0.1900 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $149M | -$27M | -$0.22 (diluted) |
| Q4 FY2025 | $166M | -$16M | -$0.13 (diluted) |
| Q1 FY2026 | $151M | -$13M | -$0.10 (diluted) |
What are the financial strengths and risks for 10x Genomics (TXG)?
Short answer
Cash and short-term investments were $575.68M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $15.83M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Cash and short-term investments substantially exceed debt and total liabilities, and the cash balance has risen across the reported history. Operating cash flow has also remained positive through most recent periods while capital spending has been modest, giving the company room to fund product development without immediate balance-sheet pressure.
That liquidity does not resolve the earnings problem. Research, selling and administrative costs still exceed gross profit, trailing margins remain negative, and the valuation stands at a demanding multiple of sales; net cash represents only a modest portion of the equity value. A prolonged spatial transition or weaker experiment volumes would pressure the consumables stream that supplies most revenue.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $15.83M Sep 30, 2026
- Previous quarter · operating cash flow
- $16.97M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $15.83M | −$970,000 |
| Jun 30, 2026 | $16.97M | −$1.59M |
| Mar 31, 2026 | $26.12M | −$1.60M |
| Dec 31, 2025 | $40.78M | −$1.78M |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at 10x Genomics (TXG)?
Short answer · as of
The next earnings report is expected on Feb 11, 2027.
Research dated 2026-09-13.
Atera shipment cadence is the most immediate operating marker. Management expects spatial transition effects to weigh on near-term revenue before shipments contribute more meaningfully later, so the useful test is whether that handoff appears in revenue without another deterioration in gross profit or operating loss.
Consumables should be watched alongside instruments because they reveal whether laboratories are actively running experiments rather than merely adopting hardware. Positive operating cash flow must also persist as consensus expectations pair revenue growth with continuing accounting losses.
What management is planning
How does 10x Genomics compare with its peers?
Short answer
10x Genomics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
TXG belongs with life-science instrument and research-platform companies rather than therapeutic biotechnology developers. Its distinction is the combination of Chromium cell-resolved workflows, Visium spatial analysis, software and proprietary consumables, creating revenue from laboratory activity after hardware placement. The consumables-heavy mix makes research usage and platform transitions more consequential than a conventional equipment replacement cycle.
| Company | Price | Market value | Score |
|---|---|---|---|
| $70.53 Nov 18, 2026 | $9.34B | 94 5-pillar Nov 18, 2026 | |
| $320.50 Nov 18, 2026 | $12.6B | 92 5-pillar Nov 18, 2026 | |
| $94.54 Nov 18, 2026 | $5.21B | 88 5-pillar Nov 18, 2026 | |
| $139.98 Nov 18, 2026 | $9.71B | 85 5-pillar Nov 18, 2026 | |
| $210.01 Nov 18, 2026 | $31.8B | 84 5-pillar Nov 18, 2026 | |
| $30.32 Nov 18, 2026 | $12.7B | 84 5-pillar Nov 18, 2026 | |
| $163.96 Nov 18, 2026 | $11.6B | 83 5-pillar Nov 18, 2026 | |
| $103.32 Nov 18, 2026 | $19.6B | 79 5-pillar Nov 18, 2026 | |
| $370.17 Nov 18, 2026 | $9.95B | 77 5-pillar Nov 18, 2026 | |
| $126.97 Nov 18, 2026 | $4.32B | 68 5-pillar Nov 18, 2026 | |
| $96.43 Nov 18, 2026 | $3.35B | 68 5-pillar Nov 18, 2026 | |
| $63.26 Nov 18, 2026 | $9.66B | 59 5-pillar Nov 18, 2026 | |
| 10x Genomics (TXG) — this page | $57.07 | $7.51B | 38 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $61.00 – $110.00
- Consensus target
- $82.40
- Median target
- $75.00
Consensus record · Captured .
Measured against a quoted price of $57.07 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 10, 2026
- Transactions
- 44
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 36
- Other transactions
- 8
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 503 Period end Sep 30, 2026
- Previous quarter · holders
- 405 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 18,138,699 |
| Price T Rowe Associates INC /Md/ | 17,470,896 |
| Blackrock, INC. | 11,574,445 |
| Ark Investment Management LLC | 6,272,998 |
| Vanguard Portfolio Management LLC | 5,914,697 |
Tracked investors
Which of the 16 named investors we follow held TXG in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| ARK Invest | Cathie Wood | Q3 2026 | 3.26% | $566.83M | Trimmed −37.3% shares |
| Viking Global | Andreas Halvorsen | Q3 2026 | 0.21% | $67.51M | New position |
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.05% | $10.53M | Added +770.9% shares |
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 0% | $0 | Sold out (was $15.46M) |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about 10x Genomics (TXG)?
What Investors Ask About 10x Genomics (TXG) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do Chromium instruments and consumables shape TXG revenue?
Chromium hardware establishes the workflow, while chips, slides and reagents are consumed as laboratories run experiments. Consumables dominate reported revenue, so usage of installed systems is the more persistent economic engine.
Why does the Visium transition to Atera matter for TXG?
Management expects the spatial transition to suppress near-term revenue before Atera shipments become a more meaningful contributor. The transition matters because delayed adoption can weaken instrument revenue and the later consumable demand attached to those platforms.
Why can Chromium and Visium sales coexist with accounting losses?
The platforms generate strong gross profit, but research and development plus selling and administrative expense still consume more than that profit. Operating cash flow can remain positive even while operating and net results are negative.
Who buys Chromium and Visium systems?
Academic, government, biotechnology and biopharmaceutical organizations use the systems for cell-resolved and spatial analysis of biological samples. Their purchases span instruments, consumables, services and software-supported workflows.
What is the TXG stock price today?
The last price recorded for 10x Genomics, Inc. (TXG), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the TXG price target?
The analyst consensus price target for 10x Genomics, Inc. (TXG), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 79 figures on this page — 2 from SEC filings and earnings calls, 68 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold TXG
Funds in our ETF coverage that list TXG among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| ARK Innovation ETF (ARKK) | 3.43% |